Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Gemcitabine
See also Cytotoxic and immunosuppressant drugs
General information
Gemcitabine is an S-phase-specific pyrimidine nucleoside analogue of deoxycytidine (2',2'-difluorodeoxycytidine) that is structurally similar to cytosine arabinoside. It has been used to treat metastatic urothelial carcinoma of the bladder, pancreatic cancer, and some other solid tumors.
Drug studies
Observational studies
In a retrospective study of patients with non-small cell lung cancers who received gemcitabine 1000 mg/m 2 on days 1 and 8, the adverse effects and reactions involved the gastrointestinal system (nausea, vomiting, and diarrhea) and the hemopoietic system (leukopenia, neutropenia, thrombocytopenia, and anemia), but only in the last (8th–11th) cycles [ ]. There was grade 4 vomiting in three patients, grade 4 thrombocytopenia in two, and grade 3 leukopenia in three. Other adverse effects and reactions were mild. None of the patients died during chemotherapy.
You're Reading a Preview
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here